Number 5: Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees ...

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for patients with inflammatory bowel disease (IBD). Number 4: Significant knowledge ...

Chad Pettit, MBA, is the executive director of global value access and policy for Amgen’s Biosimilars Business Unit. He develops global market access launch strategy for Amgen’s portfolio of 10 ...

Gary Fanjiang, MD, MBA, MS, is the vice president of global development at Amgen, where he leads research and development activities for the Biosimilars Business Unit. He oversees the nonclinical, ...